FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000986137> ?p ?o ?g. }

• W2000986137 endingPage "625" @default.
• W2000986137 startingPage "614" @default.
• W2000986137 abstract "Intermittent parathyroid hormone (PTH) therapy increases bone mass. The purpose of this study was to determine if analogs of human PTH(1-34) (hPTH[1-34]), which differ from the native sequence in their receptor-activating properties, could promote bone formation in an ovariectomized (OVX) osteopenic rat model. We synthesized two hPTH(1-34) analogs with single substitutions for serine in the 3-position that in vitro are partial agonists in kidney. In the renal cell line OK, maximal cyclic adenosine monophosphate (cAMP) activation by [His(3)]hPTH(134) was 50%, and maximal cAMP activation by [Leu(3)]hPTH(1-34) was 20% of that produced by hPTH(1-34). Both analogs were full agonists in UMR-106 rat osteosarcoma cells and other bone-derived systems, but both had reduced potency compared with hPTh(1-34). Six-month-old retired breeder Sprague-Dawley rats were ovariectomized, and five animals underwent sham operation. On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each. All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84. Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints. The cancellous bone volume was significantly lower at day 56 post-OVX (pretreatment) and at day 84 post-OVX (post-vehicle treatment) than at baseline. None of the compounds significantly increased the cancellous bone volume. Trabecular number declined after OVX and did not change with hPTH treatment. In contrast, the trabecular thickness declined after OVX but was higher after treatment with 40 mu g/kg of BW/day or 400 mu g/kg of BW/day of hPTH(1-34). In OVX rats, the mineralizing surface was higher than baseline at day 56 and fell toward control levels by day 84. All three peptides produced marked dose-related increases in the mineralizing surface and bone formation rates, but the two analogs were less potent than hPTH(1-34). Likewise, all peptides produced significant dose-related increases in the serum osteocalcin level. The osteoclast surface was not affected by OVX but was decreased with medium and high doses of hPTH(1-34). Pyridinoline cross-link excretion was not significantly affected by treatment with hPTH(1-34) but responded with a dose-dependent decrease to treatment with [His3]hPTH(1-34). These data suggest that bone selective analogs of hPTH(1-34) maintain the ability to induce bone formation but are less potent than hPTH(1-34)." @default.
• W2000986137 created "2016-06-24" @default.
• W2000986137 creator A5002436223 @default.
• W2000986137 creator A5013703333 @default.
• W2000986137 creator A5045103003 @default.
• W2000986137 creator A5048894863 @default.
• W2000986137 creator A5052367502 @default.
• W2000986137 creator A5054023743 @default.
• W2000986137 creator A5067422009 @default.
• W2000986137 date "2009-12-03" @default.
• W2000986137 modified "2023-10-10" @default.
• W2000986137 title "Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model" @default.
• W2000986137 cites W1258321623 @default.
• W2000986137 cites W1536310816 @default.
• W2000986137 cites W1537520293 @default.
• W2000986137 cites W1561488685 @default.
• W2000986137 cites W1592400272 @default.
• W2000986137 cites W1970955782 @default.
• W2000986137 cites W1972376518 @default.
• W2000986137 cites W1972828099 @default.
• W2000986137 cites W1976868129 @default.
• W2000986137 cites W1977603398 @default.
• W2000986137 cites W1980266716 @default.
• W2000986137 cites W1997473010 @default.
• W2000986137 cites W1999076184 @default.
• W2000986137 cites W2005843802 @default.
• W2000986137 cites W2015576315 @default.
• W2000986137 cites W2019308648 @default.
• W2000986137 cites W2019493445 @default.
• W2000986137 cites W2024157277 @default.
• W2000986137 cites W2042897724 @default.
• W2000986137 cites W2047312094 @default.
• W2000986137 cites W2047644681 @default.
• W2000986137 cites W2048925142 @default.
• W2000986137 cites W2061593831 @default.
• W2000986137 cites W2062513753 @default.
• W2000986137 cites W2064390254 @default.
• W2000986137 cites W2070914367 @default.
• W2000986137 cites W2084534298 @default.
• W2000986137 cites W2087378917 @default.
• W2000986137 cites W2094937528 @default.
• W2000986137 cites W2102024055 @default.
• W2000986137 cites W2122745505 @default.
• W2000986137 cites W2138384796 @default.
• W2000986137 cites W2151887581 @default.
• W2000986137 cites W2163047938 @default.
• W2000986137 cites W2169503005 @default.
• W2000986137 doi "https://doi.org/10.1002/jbmr.5650110509" @default.
• W2000986137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9157776" @default.
• W2000986137 hasPublicationYear "2009" @default.
• W2000986137 type Work @default.
• W2000986137 sameAs 2000986137 @default.
• W2000986137 citedByCount "64" @default.
• W2000986137 countsByYear W20009861372013 @default.
• W2000986137 countsByYear W20009861372014 @default.
• W2000986137 countsByYear W20009861372017 @default.
• W2000986137 countsByYear W20009861372018 @default.
• W2000986137 countsByYear W20009861372021 @default.
• W2000986137 countsByYear W20009861372023 @default.
• W2000986137 crossrefType "journal-article" @default.
• W2000986137 hasAuthorship W2000986137A5002436223 @default.
• W2000986137 hasAuthorship W2000986137A5013703333 @default.
• W2000986137 hasAuthorship W2000986137A5045103003 @default.
• W2000986137 hasAuthorship W2000986137A5048894863 @default.
• W2000986137 hasAuthorship W2000986137A5052367502 @default.
• W2000986137 hasAuthorship W2000986137A5054023743 @default.
• W2000986137 hasAuthorship W2000986137A5067422009 @default.
• W2000986137 hasConcept C125870589 @default.
• W2000986137 hasConcept C126322002 @default.
• W2000986137 hasConcept C131075544 @default.
• W2000986137 hasConcept C134018914 @default.
• W2000986137 hasConcept C142724271 @default.
• W2000986137 hasConcept C160160445 @default.
• W2000986137 hasConcept C170033053 @default.
• W2000986137 hasConcept C181199279 @default.
• W2000986137 hasConcept C185592680 @default.
• W2000986137 hasConcept C2776350087 @default.
• W2000986137 hasConcept C2778588143 @default.
• W2000986137 hasConcept C2781208988 @default.
• W2000986137 hasConcept C519063684 @default.
• W2000986137 hasConcept C55493867 @default.
• W2000986137 hasConcept C71315377 @default.
• W2000986137 hasConcept C71924100 @default.
• W2000986137 hasConcept C8264082 @default.
• W2000986137 hasConceptScore W2000986137C125870589 @default.
• W2000986137 hasConceptScore W2000986137C126322002 @default.
• W2000986137 hasConceptScore W2000986137C131075544 @default.
• W2000986137 hasConceptScore W2000986137C134018914 @default.
• W2000986137 hasConceptScore W2000986137C142724271 @default.
• W2000986137 hasConceptScore W2000986137C160160445 @default.
• W2000986137 hasConceptScore W2000986137C170033053 @default.
• W2000986137 hasConceptScore W2000986137C181199279 @default.
• W2000986137 hasConceptScore W2000986137C185592680 @default.
• W2000986137 hasConceptScore W2000986137C2776350087 @default.
• W2000986137 hasConceptScore W2000986137C2778588143 @default.
• W2000986137 hasConceptScore W2000986137C2781208988 @default.
• W2000986137 hasConceptScore W2000986137C519063684 @default.
• W2000986137 hasConceptScore W2000986137C55493867 @default.

• next